Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that using electronic healthcare record data can provide valuable early insights into the clinical context of about half of the new safety signals evaluated within a regulatory environment.

This meta-analysis concluded that 5α-reductase inhibitors may increase the risk of mild depression, particularly with dutasteride, in patients treated for benign prostatic hyperplasia and androgenic alopecia.

This study explored the optimization of phytochemicals from Alstonia boonei to develop potential 5-alpha reductase inhibitors for Benign Prostatic Hyperplasia, finding promising analogs with enhanced binding affinity and stability compared to Finasteride, warranting further experimental validation.

This review discusses the efficacy of the lipidosterolic extract of Serenoa repens for treating lower urinary tract symptoms and reports no new clinical results; the authors propose further examination of the existing literature and guidelines.

This article discusses the approval status of 5α-reductase inhibitors for androgenetic alopecia, noting finasteride is FDA-approved for certain men while dutasteride is not approved in the US for this condition; it reports no new results.

This narrative review highlights the critical role of intracrine hormone production in peripheral tissues, suggesting that continuous-release subcutaneous testosterone pellet therapy may offer a more effective symptom-driven approach for aging populations, though large-scale randomized controlled trials are needed for confirmation.

In this study of 131 healthy men aged 30 to 45, no relationship was found between androgen receptor gene polymorphisms related to androgen sensitivity and biological age markers, suggesting that other factors may influence the aging process independently of these genetic variations.

This study reported that compounds from the root of Beta vulgaris, specifically 4-picoline and Betalain, showed potential as effective anti-hair loss treatments by demonstrating significant inhibitory activity against the enzyme 5α-reductase in a computational molecular docking study.

In this study, researchers used molecular docking to show that compounds from pomegranate peels, such as apigenin, luteolin, and taxifolin, effectively inhibit the enzyme 5α-reductase, suggesting potential anti-alopecic properties.

This animal study found that finasteride, a 5-alpha reductase type 2 inhibitor, decreased dihydrotestosterone levels and c-Fos protein activation in the rat brain, but these effects may diminish after discontinuing the drug.

Different types of hair loss in dogs and cats have various causes and treatments, with outcomes ranging from good to uncertain.

Alopecia in animals can be hereditary, congenital, or acquired, with treatments and outcomes varying widely.

Treatments for hair loss vary, but cell-based options may be the future.

This article reviews how to identify and manage androgenic alopecia caused by hormonal contraceptives but reports no new clinical findings.

This article reviews the potential clinical use of anabolic steroids in treating muscle loss from chronic diseases and aging and highlights both the benefits and risks of these substances in sports.

The NAMS 2014 recommendations guide healthcare providers on treating health issues in midlife women, emphasizing individualized care and informed decision-making.

This review discusses the various treatment options for male and female pattern hair loss and provides no new clinical results; the authors outline the most effective strategies based on existing evidence.

This article reviews the historical developments in understanding and treating male pattern hair loss, emphasizing the role of dihydrotestosterone and 5α-reductase inhibitors, but reports no new clinical findings.

This review discusses recent advancements in understanding and managing congenital adrenal hyperplasia, including improvements in screening, diagnostics, and potential genetic and cell-based treatments, but reports no new clinical findings.

This review concluded that oral finasteride for men and topical minoxidil for both genders have the most evidence supporting their effectiveness and safety for treating androgenetic alopecia.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

This article suggests that modern lifestyle changes, including diet, stress, and chronic anti-inflammatory medication use, may disrupt the natural process of inflammation resolution, increasing vulnerability to chronic disease.

This article reviews recent advancements in understanding and treating androgenetic alopecia, focusing on new genetic insights, stem cell roles, and diagnostic tools, without reporting new clinical results.

New treatments for male hypogonadism are effective and should be personalized.

This study found that low-dose finasteride use in young men was associated with higher reporting of persistent sexual dysfunction, with some cases linked to suicidal ideation.

This review discusses phytotherapy options for managing benign prostatic hyperplasia, noting some herbal agents show promise in trials for mild-moderate symptoms but more evidence is needed for others.

This review discusses hormone replacement therapy for women with premature ovarian insufficiency, strongly recommending it for symptom relief and bone protection, but notes a lack of evidence on optimal types and doses.

This study found low- to very low-quality evidence suggesting that several pharmacological treatments, including alpha blockers and antibiotics, may reduce prostatitis symptoms without significantly increasing adverse events in the short term, although more rigorous trials are needed.

This review discusses common skin appendage diseases, including their pathophysiology and treatments, but does not report new results.

This review discusses the physiopathology of androgenetic alopecia and evaluates various traditional and emerging treatments, reporting no new clinical results but highlighting the need for enhanced treatment strategies.